Skip to content

An Endometrial Cancer Chemoprevention Study of Metformin

An Endometrial Cancer Chemoprevention Study of Metformin Versus No Treatment in Women With a Body Mass Index (BMI) >/= 30 kg.m2 and Hyperinsulinemia

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01697566
Enrollment
29
Registered
2012-10-02
Start date
2013-05-30
Completion date
2024-05-30
Last updated
2025-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecology

Keywords

Gynecology, Endometrial Cancer Chemoprevention, Obese, Body Mass Index (BMI) >/= 35 kg.m2, Post-menopausal, Hyperinsulinemia, Metformin, Placebo, Sugar pill, Lifestyle intervention, Diet, Exercise

Brief summary

The goal of this clinical research study is to learn about the effects of metformin and/or a program called lifestyle intervention on the endometrium (inner lining of the uterus) in post-menopausal women who are also obese (both are risk factors for endometrial cancer). Researchers also want to learn how insulin levels will be affected by metformin, diet and/or exercise. Metformin is designed to treat both diabetes and insulin resistance. Insulin resistance is a condition in which the body makes insulin but does not use it properly. It is often referred to as pre-diabetes. Many people with insulin resistance have high levels of both sugar and insulin in their blood at the same time, which have been reported in patients with endometrial cancer. In this study, metformin will be compared to a placebo. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect. Lifestyle intervention is made up of a series of in-person sessions where you meet with a coach to discuss strategies for losing weight and ways to increase physical activity. It also consists of materials designed to help you lose weight and will offer opportunities for supervised exercise.

Detailed description

Study Groups: If you are found to be eligible to take part in this study, you will be randomly assigned (as in the roll of dice) to 1 of 4 study groups: * Metformin only. * Placebo and lifestyle intervention. * Metformin and lifestyle intervention. * Placebo only. Neither you nor the study staff will know if you are receiving metformin or placebo. However, if needed for your safety, the study staff will be able to find out what you are receiving. In the first month you will gradually increase the dose of metformin/placebo by mouth as listed below: * Week 1: One capsule each day * Week 2: One capsule 2 times each day * Week 3: One capsule 3 times each day * Week 4: Two capsules 2 times each day After week 4, you will continue to take 2 capsules of metformin/placebo 2 times each day. If you are receiving the lifestyle intervention, you will have 16 lifestyle intervention sessions over 4 months. At each of these sessions, you will discuss methods for managing your weight. You will receive print materials and worksheets, measuring utensils, and a food scale. You will be instructed how to use each of these materials and how often to use them during the study. You will also be provided with opportunities for supervised exercise (such as group exercise class and group walks). If you are traveling during a scheduled session, it can be performed over the telephone. Each call should last about 30 minutes, during which you will discuss the same goals and information that you would discuss in the in-person sessions. Study Visits: Before you can begin receiving the study drug/placebo: * At the second screening visit , you will have a dual energy x-ray absorptiometry (DEXA) scan to measure your body composition. The scan requires you to lie still on a table for about 8-10 minutes while a low-energy x-ray takes an image that allows the study staff to get an image of your body fat density. * You will be given an accelerometer (a small, portable device that measures your physical activity) and be taught how to use it at the first Screening Visit. You will wear the accelerometer at all times while you are awake for 7 days. At the second Screening Visit, you will return the accelerometer at an intervention session. If you are not able to return it at the second visit then you will mail it back to the study staff in a pre-paid envelope. You will receive the accelerometer again at Month 4 and wear it for another 7 days. * You will receive a study diary in which you will record any and all exercise you perform each day while you are on study. It should take about 5 minutes to complete each time. * You will complete questionnaires about diet and exercise. These questionnaires should take about 30-40 minutes to complete. * You will also be taught to complete a questionnaire on the internet to record the food you eat in a 24 hour period. You will do this 3 times over a 2 week period. The first time, you will complete it at the clinic. The study staff will call and remind you to complete the questionnaire the other 2 times. Each time you complete this questionnaire, it should take about 40 minutes. At Month 1, all participants will return for a study visit. The following tests and procedures will be performed: * Blood (about 2 teaspoons) will be drawn for routine tests. If this blood draw shows that your liver or kidney function is abnormal, you will need to return for an additional blood °draw at Month 2. * If you are having symptoms that you would describe as moderate or worse, you will have a non-pelvic physical exam including measurement of your vital signs and any unreported symptoms you may be having. At each month, you will be asked about any symptom(s) that you may have to learn if it is related to the study. If you are called, this phone call should last about 5 minutes. If you are asked in a in-person visit, the visit can last up to an hour. Length of Study: You will receive the study drug/placebo and/or lifestyle intervention for up to 4 months. You will be taken off study if you have intolerable side effects or if you develop endometrial cancer or hyperplasia during the study. Your participation in the study will be over after the end-of-study visit. Post-Treatment Visit: At the end of the 4th month, you will have a post-treatment visit. You will repeat all procedures performed in the first and second visit: * Your height, weight, waist, and hip circumference will be measured. * You will have a DEXA scan. * You will complete the questionnaires about food, diet, and exercise. * You will be given a questionnaire about your satisfaction (based on the intervention) to complete and return at this visit. This questionnaire will take up to an hour to complete. * You will have an endometrial biopsy. * Blood (about 8 tablespoons) will be drawn for routine tests and for biomarker testing. You will have to fast (not eat or drink anything except water) for 12 hours before this blood draw. * You will complete the questionnaire on the internet to record the food you eat in a 24 hour period. You will do this 3 times over a 2 week period. The first time, you will complete it at the clinic. The study staff will call and remind you to complete the questionnaire the other 2 times. Each time you complete this questionnaire, it should take about 40 minutes. Follow-Up: About 1 year after the screening visits (+/- 1 month), the following tests and procedures will be performed: * Your height, weight, waist, and hip circumference will be measured. * You will have a DEXA scan. * Blood (about 8 tablespoons) will be drawn for routine tests and for biomarker testing. °You will have to fast (not eat or drink anything except water) for 12 hours before this blood draw. * You will wear the accelerometer for 7 days. * You will complete questionnaires about food, diet, and exercise. * You will complete the questionnaire on the internet to record the food you eat in a 24 hour period. You will do this 3 times over a 2 week period. The first time, you will complete it at the clinic. The study staff will call and remind you to complete the questionnaire the other 2 times. Each time you complete this questionnaire, it should take about 40 minutes. This is an investigational study. Metformin is FDA approved and commercially available for the treatment of diabetes and insulin resistance. Up to 100 patients will take part in this study. All will be enrolled at MD Anderson Cancer Center.

Interventions

DRUGMetformin

Participants gradually increase the dose of metformin by mouth as listed below: Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day After week 4, participant continues to take 2 capsules of metformin 2 times each day. Each capsule is 425 mg.

OTHERPlacebo

Placebo taken by mouth twice daily for 4, 30 day cycles.

PROCEDUREEndometrial Biopsy

Endometrial biopsies obtained at baseline and after 4 months.

BEHAVIORALLifestyle Intervention

Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.

BEHAVIORALQuestionnaires

Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
50 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. For this study, only women will be enrolled. 2. Body Mass Index (BMI) \> or = 30 kg/m2 3. Not frankly diabetic, as measured by a fasting blood glucose \</=126 mg/dL. 4. Demonstrate hyperinsulinemia with a QUICK I value \</= 0.357. 5. Age \>/= 50 and \</= 65 6. Zubrod Performance Scale 0-1 7. Hemoglobin \>/= 10 g/dl 8. TSH 0.27 - 4.20 µlU/mL 9. Menopause as defined as no menses for 1 year and/or FSH \>/= 25.8 mIU/ml 10. Must be able to read, write, and speak English. 11. Must have a Primary Care Provider (PCP).

Exclusion criteria

1. Prior hysterectomy or endometrial ablation 2. ALT \>/r = 2.0x Upper Limit of Normal (ULN) 3. Serum creatinine \> /= 1.4 mg/dl 4. Triglycerides (fasting) \>/ = 400 5. Known inability to participate in the ongoing appointments for the four months of the study and scheduled follow-up tests. 6. Significant medical or psychiatric history which would make the participant a poor protocol candidate, in the opinion of the principal investigator, for any aspect of study participation including metformin, unsupervised exercise program or dietary behavior change. 7. Participant reported history of congestive heart failure 8. Prior treatment with Metformin 9. Currently being treated for diabetes or meeting criteria for new diagnosis of diabetes. 10. Known allergy to Metformin or other biguanide (Proguanil). 11. Use of Aromatase Inhibitors, GNRH-agonists i.e.Lupron, Zoladex within the last 6 months 12. Use of SERMS (selective estrogen receptor modulators) in the past 6 months, including Tamoxifen and Raloxifene 13. Hormone replacement therapy within the last 6 months 14. Women who have been treated with chemotherapy for prior malignant disease or currently have an untreated malignancy other than non-melanoma skin cancer 15. Patients who have had prior radiation to the pelvis

Design outcomes

Primary

MeasureTime frameDescription
To Evaluate the Participant Body Weight in Pounds (Lbs)Visit 2 (1 week), 4 months, and 1 yearThis study will use a 2 x 2 randomized design with all 100 post- menopausal subjects being randomized to metformin, placebo, placebo and intensive lifestyle intervention, or metformin and intensive lifestyle intervention. Treatments will last 4 months. Participants will be assessed at baseline and end of treatment with endometrial sampling to see if there are changes in the biomarkers.
To Evaluate the Percentage of Ki-67 Positive CellsVisit 2 (1 week), 4 months, and 1 yearThe Q-PCR analyses will be performed in the Quantitative Genomics Core Facility at the University of Texas Medical School at Houston. Over the last 3 years we have used several techniques including differential display, microchip array screening, and real-time quantitative PCR to find such genes. The tools we have developed are directly applicable to the investigation of surrogate endpoint biomarkers (SEBs). Identification of appropriate biomarkers is essential for this study.

Secondary

MeasureTime frame
BMIVisit 2 (1 week), 4 months, and 1 year
Weight LossVisit 2 (1 week), 4 months, and 1 year

Countries

United States

Participant flow

Recruitment details

Recruitment was from May 2013 until May 2016 and all recruitments were done in a medical clinic setting.

Participants by arm

ArmCount
Metformin + Lifestyle
Metformin 1700 mg daily along with lifestyle intervention program
7
Metformin + No Lifestyle
Metformin 1700 mg daily with no lifestyle intervention program
7
Placebo + Lifestyle
Placebo given daily along with lifestyle intervention program
7
Placebo + No Lifestyle
Placebo given daily with no lifestyle intervention program
8
Total29

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Overall StudyFinal biopsy not obtained0010
Overall StudyWithdrawal by Subject0011

Baseline characteristics

CharacteristicMetformin + LifestyleMetformin + No LifestylePlacebo + LifestylePlacebo + No LifestyleTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
7 Participants7 Participants7 Participants8 Participants29 Participants
Age, Continuous56.3 years56 years57 years59.8 years57.4 years
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants1 Participants2 Participants2 Participants5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
4 Participants4 Participants2 Participants4 Participants14 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
3 Participants2 Participants3 Participants2 Participants10 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
5 Participants1 Participants2 Participants4 Participants12 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants1 Participants1 Participants2 Participants4 Participants
Race (NIH/OMB)
White
2 Participants5 Participants4 Participants2 Participants13 Participants
Region of Enrollment
United States
7 participants7 participants7 participants8 participants29 participants
Sex: Female, Male
Female
7 Participants7 Participants7 Participants8 Participants29 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 70 / 70 / 70 / 8
other
Total, other adverse events
4 / 76 / 74 / 74 / 8
serious
Total, serious adverse events
0 / 70 / 70 / 70 / 8

Outcome results

Primary

To Evaluate the Participant Body Weight in Pounds (Lbs)

This study will use a 2 x 2 randomized design with all 100 post- menopausal subjects being randomized to metformin, placebo, placebo and intensive lifestyle intervention, or metformin and intensive lifestyle intervention. Treatments will last 4 months. Participants will be assessed at baseline and end of treatment with endometrial sampling to see if there are changes in the biomarkers.

Time frame: Visit 2 (1 week), 4 months, and 1 year

ArmMeasureGroupValue (MEAN)Dispersion
Metformin + LifestyleTo Evaluate the Participant Body Weight in Pounds (Lbs)Weight Year 1102.08 lbsStandard Deviation 35.32
Metformin + LifestyleTo Evaluate the Participant Body Weight in Pounds (Lbs)Weight Visit 2108.57 lbsStandard Deviation 22.51
Metformin + LifestyleTo Evaluate the Participant Body Weight in Pounds (Lbs)Weight Month 4101.19 lbsStandard Deviation 22.47
Metformin + No LifestyleTo Evaluate the Participant Body Weight in Pounds (Lbs)Weight Year 195.93 lbsStandard Deviation 12.63
Metformin + No LifestyleTo Evaluate the Participant Body Weight in Pounds (Lbs)Weight Visit 299.3 lbsStandard Deviation 15.36
Metformin + No LifestyleTo Evaluate the Participant Body Weight in Pounds (Lbs)Weight Month 496.39 lbsStandard Deviation 15.36
Placebo + LifestyleTo Evaluate the Participant Body Weight in Pounds (Lbs)Weight Month 497.98 lbsStandard Deviation 16.46
Placebo + LifestyleTo Evaluate the Participant Body Weight in Pounds (Lbs)Weight Visit 2101.64 lbsStandard Deviation 13.44
Placebo + LifestyleTo Evaluate the Participant Body Weight in Pounds (Lbs)Weight Year 193.25 lbsStandard Deviation 8.15
Placebo + No LifestyleTo Evaluate the Participant Body Weight in Pounds (Lbs)Weight Visit 294.1 lbsStandard Deviation 12.89
Placebo + No LifestyleTo Evaluate the Participant Body Weight in Pounds (Lbs)Weight Year 194.96 lbsStandard Deviation 13.68
Placebo + No LifestyleTo Evaluate the Participant Body Weight in Pounds (Lbs)Weight Month 494.37 lbsStandard Deviation 13.46
Comparison: Body Weightp-value: 0.006t-test, 2 sided
Comparison: Fat Massp-value: <0.001t-test, 2 sided
Primary

To Evaluate the Percentage of Ki-67 Positive Cells

The Q-PCR analyses will be performed in the Quantitative Genomics Core Facility at the University of Texas Medical School at Houston. Over the last 3 years we have used several techniques including differential display, microchip array screening, and real-time quantitative PCR to find such genes. The tools we have developed are directly applicable to the investigation of surrogate endpoint biomarkers (SEBs). Identification of appropriate biomarkers is essential for this study.

Time frame: Visit 2 (1 week), 4 months, and 1 year

ArmMeasureGroupValue (MEAN)Dispersion
Metformin + LifestyleTo Evaluate the Percentage of Ki-67 Positive CellsVisit 28.78 percentage of cellsStandard Deviation 8.29
Metformin + LifestyleTo Evaluate the Percentage of Ki-67 Positive CellsMonth 46.73 percentage of cellsStandard Deviation 4.17
Metformin + No LifestyleTo Evaluate the Percentage of Ki-67 Positive CellsMonth 44.98 percentage of cellsStandard Deviation 3.94
Metformin + No LifestyleTo Evaluate the Percentage of Ki-67 Positive CellsVisit 27.95 percentage of cellsStandard Deviation 5.13
Placebo + LifestyleTo Evaluate the Percentage of Ki-67 Positive CellsVisit 29.23 percentage of cellsStandard Deviation 3.96
Placebo + LifestyleTo Evaluate the Percentage of Ki-67 Positive CellsMonth 44.17 percentage of cellsStandard Deviation 2.37
Placebo + No LifestyleTo Evaluate the Percentage of Ki-67 Positive CellsVisit 24.73 percentage of cellsStandard Deviation 1.39
Placebo + No LifestyleTo Evaluate the Percentage of Ki-67 Positive CellsMonth 49.1 percentage of cellsStandard Deviation 5.96
Secondary

BMI

Time frame: Visit 2 (1 week), 4 months, and 1 year

ArmMeasureGroupValue (MEAN)Dispersion
Metformin + LifestyleBMIBMI Visit 245.25 weight (kg) / height (m)2Standard Deviation 9.36
Metformin + LifestyleBMIBMI Year 141.13 weight (kg) / height (m)2Standard Deviation 13.45
Metformin + LifestyleBMIBMI Month 439.83 weight (kg) / height (m)2Standard Deviation 7.82
Metformin + No LifestyleBMIBMI Visit 238.17 weight (kg) / height (m)2Standard Deviation 5.18
Metformin + No LifestyleBMIBMI Year 137.18 weight (kg) / height (m)2Standard Deviation 4.41
Metformin + No LifestyleBMIBMI Month 437.34 weight (kg) / height (m)2Standard Deviation 4.78
Placebo + LifestyleBMIBMI Month 437.83 weight (kg) / height (m)2Standard Deviation 5.53
Placebo + LifestyleBMIBMI Visit 239.49 weight (kg) / height (m)2Standard Deviation 4.71
Placebo + LifestyleBMIBMI Year 136 weight (kg) / height (m)2Standard Deviation 2.3
Placebo + No LifestyleBMIBMI Visit 235.29 weight (kg) / height (m)2Standard Deviation 4
Placebo + No LifestyleBMIBMI Year 135.54 weight (kg) / height (m)2Standard Deviation 4.23
Placebo + No LifestyleBMIBMI Month 435.31 weight (kg) / height (m)2Standard Deviation 4.16
p-value: 0.019t-test, 2 sided
Secondary

Weight Loss

Time frame: Visit 2 (1 week), 4 months, and 1 year

ArmMeasureGroupValue (MEAN)Dispersion
Metformin + LifestyleWeight LossWeight Loss (Month 4 - Visit 2)/Visit 2-7.10 percentage of weight lossStandard Deviation 5.22
Metformin + LifestyleWeight LossWeight Loss (Year 1 - Visit 2)/Visit 2-5.49 percentage of weight lossStandard Deviation 13.51
Metformin + No LifestyleWeight LossWeight Loss (Year 1 - Visit 2)/Visit 2-3.09 percentage of weight lossStandard Deviation 3.45
Metformin + No LifestyleWeight LossWeight Loss (Month 4 - Visit 2)/Visit 2-2.95 percentage of weight lossStandard Deviation 2.34
Placebo + LifestyleWeight LossWeight Loss (Year 1 - Visit 2)/Visit 2-3.37 percentage of weight lossStandard Deviation 4.92
Placebo + LifestyleWeight LossWeight Loss (Month 4 - Visit 2)/Visit 2-3.88 percentage of weight lossStandard Deviation 5.11
Placebo + No LifestyleWeight LossWeight Loss (Month 4 - Visit 2)/Visit 20.25 percentage of weight lossStandard Deviation 1.61
Placebo + No LifestyleWeight LossWeight Loss (Year 1 - Visit 2)/Visit 20.83 percentage of weight lossStandard Deviation 0.95

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026